Coverage and Royalty Sample Clauses

Coverage and Royalty. The license agreement between Pfizer and MPP covers “the treat- ment and/or prevention of COVID-19 caused by SARS-Cov-2.”184 If a new use of the medicine is discovered in the future, the agreement does not apply. This limitation is consistent with similar license agree- ments that MPP signed with other pharmaceutical companies in the past.185 The license that Pfizer grants to MPP is non-exclusive, which means that Pfizer expressly reserves all its rights under the patents.186 Therefore, Pfizer is free to grant additional licenses or distribute the products to a third party and “make, use, import, offer for sale and/or donate” the products on its own behalf.187 Licensees must refrain from infringing or misappropriating Pfizer’s patents, know-how, confiden- tial information, and other IP rights.188 In addition, the license is non- transferrable but sublicensable.189 Thus, MPP does not have a right to transfer the ownership to a third party. MPP has limited the regranting of the right to a licensee by one tier.190 In other words, a licensee is not permitted to re-sublicense the right to another party.191 Once re- ceiving the grant of license from MPP, a licensee has the right to man- ufacture the licensed product at a facility within the territory 181. Press Release, PFIZER, Pfizer’s Novel COVID-19 Oral Antiviral Treatment Can- didate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study (Nov. 5, 2021, 6:45AM), xxxxx://xxx.xxxxxx.xxx/news/press-re- lease/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate. 182. Press Release, Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, FOOD & DRUG ADMIN. (Dec. 2021), https:// xxx.xxx.xxx/xxxx-xxxxxx/xxxxx-xxxxxxxxxxxxx/xxxxxxxxxxx-xxxxx-00-xxxxxx-xxx-xx- thorizes-first-oral-antiviral-treatment-covid-19. 183. See generally PFIZER-MPP AGREEMENT, supra note 180. 184. Id. at §1.10. 185. Cox, supra note 174, at 304. R 186. PFIZER-MPP AGREEMENT, supra note 180, at §2.1. 187. Id. §2.5. 188. Id. §2.4. 189. Id. §2.1(a)-(f). 190. Id. 191. Id. §2.3. 28 LEGISLATION AND PUBLIC POLICY [Vol. 25:1 authorized in this agreement.192 In addition, licensees have the right to commercialize, retail, register, sell, or import/export the licensed prod- uct by itself or through its affiliates for the defined use and within the authorized territory.193 The territory that Pfizer agrees to grant licenses in consists of ninety-five countri...
AutoNDA by SimpleDocs

Related to Coverage and Royalty

  • PATENTS AND ROYALTIES Unless otherwise provided, the Contractor shall be solely responsible for obtaining the right to use any patented or copyrighted materials in the performance of the contract resulting from this Invitation for Bids. The Contractor, without exception, shall indemnify and save harmless the County and its employees from liability of any nature or kind, including cost and expenses for or on account of any copyrighted, patented, or unpatented invention, process, or article manufactured or supplied by the Contractor. In the event of any claim against the County of copyright or patent infringement, the County shall promptly provide written notification to the Contractor. If such a claim is made, the Contractor shall use its best efforts to promptly purchase for the County any infringing products or services or procure a license, at no cost to the County, which will allow continued use of the service or product. If none of the alternatives are reasonably available, the County agrees to return the article on request to the Contractor and receive reimbursement, if any, as may be determined by a court of competent jurisdiction.

  • Coverage and Application 1. This Agreement shall apply with respect to the avoidance or settlement of all disputes arising between the Parties under the covered agreements. Unless otherwise provided in this Agreement or any other covered agreement, this Agreement shall apply to all disputes between the Parties.

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

  • Royalty Licensee shall pay Licensor a royalty equal to the Royalty Rate times Net Sales.

  • Minimum scope of coverage Commercial general coverage shall be at least as broad as Insurance Services Office Commercial General Liability occurrence form CG 0001 (ed. 11/88) or Insurance Services Office form number GL 0002 (ed. 1/73) covering comprehensive General Liability and Insurance Services Office form number GL 0404 covering Broad Form Comprehensive General Liability. Automobile coverage shall be at least as broad as Insurance Services Office Automobile Liability form CA 0001 (ed. 12/90) Code 1 (“any auto”). No endorsement shall be attached limiting the coverage.

  • Royalties 1. Royalties arising in a Contracting State and paid to a resident of the other Contracting State may be taxed in that other State.

  • Minimum Scope of Insurance Coverage shall be at least as broad as:

  • License Type Your license to a Product will be under a Named User or CPU license type, as specified on an order. Each Named User license to a Product entitles a Named User to access and use that Product in one production environment and up to two non-production environments. Each CPU license to a Product entitles you to assign the Product to a single CPU in one production environment and up to two non-production environments, for use in support of an unspecified number of Named Users.

  • License Types The following License Types may be offered with respect to individual Software products or product families. Additional license types may be specified with respect to certain products or product groups as set forth in the Product Specific Terms. The License Type will be specified in an LSDA.

  • License Fees If so provided in the Prospectus, the Depositor may enter into a Licensing Agreement (the "Agreement") with a licensor (the "Licensor") described in the Prospectus in which the Trust(s), as consideration for the licenses granted by the Licensor for the right to use its trademarks and trade names, intellectual property rights or for the use of databases and research owned by the Licensor, will pay a fee set forth in the Agreement to the applicable Licensor or the Depositor to reimburse the Depositor for payment of the expenses. If the Agreement provides for an annual license fee computed in whole or part by reference to the average daily net asset value of the Trust assets, for purpose of calculating the accrual of estimated expenses such annual fee shall accrue at a daily rate and the Trustee is authorized to compute an estimated license fee payment (i) until the Depositor has informed the Trustee that there will be no further deposits of additional Securities, by reference to an estimate of the average daily net asset value of the Trust assets which the Depositor shall provide the Trustee, (ii) thereafter and during the calendar quarter in which the last business day of the period described in clause (i) occurs, by reference to the net asset value of the Trust assets as of such last business day, and (iii) during each subsequent calendar quarter, by reference to the net asset value of the Trust assets as of the last business day of the preceding calendar quarter. The Trustee shall adjust the net asset value (Trust Fund Evaluation) as of the dates specified in the preceding sentence to account for any variation between accrual of estimated license fee and the license fee payable pursuant to the Agreement, but such adjustment shall not affect calculations made prior thereto and no adjustment shall be made in respect thereof.

Time is Money Join Law Insider Premium to draft better contracts faster.